Invention Grant
- Patent Title: Heterocyclic inhibitors of kinases
-
Application No.: US10464139Application Date: 2003-06-18
-
Publication No.: US07084160B2Publication Date: 2006-08-01
- Inventor: Robert M. Borzilleri , Rajeev S. Bhide , John S. Tokarski , Peter Zheng , Ligang Qian , Zhen-Wei Cai
- Applicant: Robert M. Borzilleri , Rajeev S. Bhide , John S. Tokarski , Peter Zheng , Ligang Qian , Zhen-Wei Cai
- Applicant Address: US NJ Princeton
- Assignee: Bristol-Myers Squibb Company
- Current Assignee: Bristol-Myers Squibb Company
- Current Assignee Address: US NJ Princeton
- Agent Elliott Korsen
- Main IPC: A61K31/44
- IPC: A61K31/44 ; C07D417/12
Abstract:
The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2, FGFR-1, thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.
Public/Granted literature
- US20040077696A1 Heterocyclic inhibitors of kinases Public/Granted day:2004-04-22
Information query
